Home
/ Immunomedics
/ Financials & Metrics

Immunomedics (IMMU) stock price, revenue, and financials

Immunomedics market cap is $20.3 b, and annual revenue was $295 k in FY 2019

View Company

$20.3 B

IMMU Mkt cap, 26-Oct-2020

$20.1 M

Immunomedics Revenue Q2, 2020

Immunomedics Gross profit (Q2, 2020)18.4 M

Immunomedics Gross profit margin (Q2, 2020), %91.7%

Immunomedics Net income (Q2, 2020)-66.5 M

Immunomedics EBIT (Q2, 2020)-53 M

Immunomedics Cash, 30-Jun-2020971.2 M

Immunomedics EV19.3 B

Immunomedics Revenue

Immunomedics revenue was $295 k in FY, 2019 which is a 86.3% year over year decrease from the previous period.

Embed Graph

Immunomedics Revenue Breakdown

Business Segment

Embed Graph

Immunomedics revenue breakdown by business segment: 15.3% from License fee and other revenues, 15.1% from Research and development and 69.6% from Product sales

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Revenue	3.1m	2.2m	295.0k
Revenue growth, %	(4%)	(30%)	(86%)
Cost of goods sold	482.7k	613.6k
Gross profit	2.6m	1.5m	295.0k
Gross profit Margin, %	84%	72%	100%
Sales and marketing expense	873.2k	6.8m	26.5m
R&D expense	51.8m	99.3m	254.9m
General and administrative expense	29.1m	36.5m	43.8m
Operating expense total	81.8m	142.6m	325.1m
EBIT	(79.1m)	(141.0m)	(324.8m)
EBIT margin, %	(2560%)	(6542%)	(110115%)
Interest expense	5.5m	23.3m	40.3m
Pre tax profit	(153.2m)	273.7m	(357.3m)
Income tax expense	20.9k	155.8k
Net Income	(153.2m)	273.9m	(357.3m)
EPS	(1.5)	(1.8)	(0.8)

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020
Revenue	690.5k	597.3k	482.2k						20.1m
Cost of goods sold	70.2k	496.6k	46.8k						1.7m
Gross profit	620.3k	100.7k	435.4k						18.4m
Gross profit Margin, %	90%	17%	90%						92%
Sales and marketing expense	226.1k	1.2m	2.4m	5.8m	7.9m	6.3m	5.9m	8.1m	12.9m
R&D expense	17.3m	25.5m	28.8m	38.2m	58.2m	52.9m	69.0m	62.4m	42.6m
General and administrative expense	4.7m	2.8m	6.9m	13.1m	13.6m	7.9m	11.9m	11.5m	16.0m
Operating expense total	22.2m	29.5m	38.1m	57.2m	79.6m	67.2m	86.8m	82.0m	71.4m
EBIT	(21.6m)	(29.4m)	(37.6m)	(57.2m)	(79.6m)	(67.2m)	(86.8m)	(82.0m)	(53.0m)
EBIT margin, %	(3128%)	(4927%)	(7803%)						(264%)
Interest expense	2.6m	274.0k	10.9m	10.1m	10.0m	10.6m	9.7m	13.5m	14.2m
Pre tax profit	(118.8m)	(2.5m)	(35.6m)	(64.2m)	(87.4m)	(76.0m)	(94.3m)	(93.1m)	(66.5m)
Net Income	(118.8m)	(2.5m)	(35.6m)	(64.2m)	(87.4m)	(76.0m)	(94.3m)	(93.1m)	(66.5m)
EPS	(1.0)	0.0	(0.2)	(0.3)	(0.5)	(0.4)	(0.5)	(0.4)	(0.3)

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Cash	43.4m	612.1m	608.6m
Accounts Receivable	488.7k	45.8k	295.0k
Prepaid Expenses	891.3k	3.8m	21.8m
Inventories	580.0k
Current Assets	157.3m	648.4m	638.7m
PP&E	5.2m	15.7m	32.8m
Total Assets	162.6m	664.2m	671.7m
Accounts Payable	31.4m	31.7m	60.9m
Short-term debt	90.7m	9.0m	7.4m
Current Liabilities	122.2m	43.7m	71.8m
Long-term debt	98.1m	19.8m	10.0m
Total Debt	188.8m	28.7m	17.4m
Total Liabilities	222.0m	264.5m	404.5m
Common Stock	1.1m	1.9m	2.1m
Additional Paid-in Capital	462.7m	1.2b	1.6b
Retained Earnings	(521.7m)	(795.5m)	(1.3b)
Total Equity	(59.5m)	399.7m	267.2m
Debt to Equity Ratio	-3.2 x	0.1 x	0.1 x
Debt to Assets Ratio	1.2 x	0 x	0 x
Financial Leverage	-2.7 x	1.7 x	2.5 x

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020
Cash	43.0m	61.0m	306.7m	580.6m	437.9m	427.9m	364.7m	536.3m	971.2m
Accounts Receivable	427.2k	343.3k	195.0k						22.3m
Prepaid Expenses	5.1m	4.7m	4.3m	8.5m	4.9m	8.3m	7.6m	17.3m	21.1m
Inventories	527.7k	43.3k							20.8m
Current Assets	147.4m	148.6m	369.2m	594.0m	448.9m	442.3m	378.1m	561.7m	1.0b
PP&E	6.0m	7.3m	10.7m	18.6m	35.4m	35.2m	33.4m	32.2m	33.5m
Total Assets	153.4m	156.0m	379.9m	612.7m	484.6m	477.7m	411.7m	594.1m	1.1b
Accounts Payable	33.4m	20.0m	23.2m	33.7m	53.9m	39.0m	54.6m	59.3m	59.9m
Short-term debt	165.8m	97.9m	70.3m	6.0m	298.0k	271.0k	316.0k	346.0k	356.0k
Current Liabilities	199.4m	118.0m	93.6m	44.2m	56.9m	44.6m	58.1m	67.1m	81.3m
Long-term debt	19.7m	19.7m	19.7m	19.8m	17.3m	17.2m	17.1m	9.9m	9.8m
Total Debt	185.5m	117.6m	90.1m	25.8m	17.6m	17.5m	17.5m	10.2m	10.1m
Total Liabilities	220.7m	139.5m	308.1m	273.3m	302.8m	363.1m	388.4m	409.2m	484.9m
Common Stock	1.5m	1.6m	1.7m	1.9m	1.9m	1.9m	1.9m	2.1m	2.3m
Additional Paid-in Capital	573.1m	659.5m	750.4m	1.2b	1.2b	1.2b	1.2b	1.6b	2.1b
Retained Earnings	(640.5m)	(643.0m)	(678.5m)	(859.7m)	(1.0b)	(1.1b)	(1.2b)	(1.4b)	(1.5b)
Total Equity	(67.4m)	16.4m	71.8m	339.3m	181.8m	114.6m	23.4m	184.9m	592.2m
Debt to Equity Ratio	-2.8 x	7.2 x	1.3 x	0.1 x	0.1 x	0.2 x	0.7 x	0.1 x	0 x
Debt to Assets Ratio	1.2 x	0.8 x	0.2 x	0 x	0 x	0 x	0 x	0 x	0 x
Financial Leverage	-2.3 x	9.5 x	5.3 x	1.8 x	2.7 x	4.2 x	17.6 x	3.2 x	1.8 x

Annual

USD	FY, 2017	FY, 2018	FY, 2019
Net Income	(153.3m)	(273.9m)	(357.3m)
Depreciation and Amortization	923.3k	1.3m	3.8m
Accounts Receivable	102.6k	452.3k	(295.0k)
Inventories	(196.0k)	580.0k
Accounts Payable	15.8m	(1.5m)	30.0m
Cash From Operating Activities	(62.3m)	(134.0m)	(222.4m)
Purchases of PP&E	(1.8m)	(10.0m)	(6.8m)
Cash From Investing Activities	(76.3m)	74.8m	(6.8m)
Cash From Financing Activities	168.8m	627.9m	347.2m
Net Change in Cash	30.2m	568.7m	117.9m
Interest Paid	4.8m	2.9m	338.0k
Income Taxes Paid	23.6k

Quarterly

USD	Q1, 2018	Q2, 2018	Q3, 2018	Q1, 2019	Q1, 2019	Q2, 2019	Q3, 2019	Q1, 2020	Q2, 2020
Net Income	(118.8m)	(121.3m)	(156.8m)	(64.2m)	(87.4m)	(163.4m)	(257.7m)	(93.1m)	(159.6m)
Depreciation and Amortization	212.5k	627.7k	940.3k	591.0k	804.0k	1.8m	2.8m	960.0k	1.9m
Accounts Receivable			293.7k						(22.0m)
Inventories			580.0k						(20.8m)
Accounts Payable			(9.5m)
Cash From Operating Activities	(20.6m)	(63.8m)	(96.0m)	(49.7m)	(54.7m)	(67.2m)	(129.8m)	(71.9m)	(102.7m)
Purchases of PP&E	(788.5k)	(2.0m)	(4.9m)	(3.2m)	(2.1m)	(5.7m)	(6.5m)	(473.0k)	(1.3m)
Cash From Investing Activities	14.1m	30.7m	54.5m	18.6m	(2.1m)	(5.7m)	(6.5m)	(473.0k)	(1.3m)
Cash From Financing Activities	6.0m	50.6m	304.7m	339.0k	1.8m	7.9m	8.1m	32.0k	466.6m
Net Change in Cash	(434.3k)	17.6m	263.4m	(30.7m)	(54.9m)	(65.0m)	(128.2m)	(72.3m)	362.6m
Interest Paid	2.4m	2.4m	2.9m	475.0k	169.0k	169.0k	338.0k	169.0k	169.0k

USD	FY, 2017
Revenue/Employee	23.6k
Debt/Equity	-3.2 x
Debt/Assets	1.2 x
Financial Leverage	-2.7 x

Immunomedics's Properties was reported to be 2 in FY, 2019.

	FY, 2017	FY, 2018	FY, 2019	Sep, 2020
Approval Phase Products		1	1
Office and Other Space, sq. ft.	130.7 k	136.5 k	130.7 k
Patent Applications (US)				275
Patents (US)				390
Phase I Trials Products		1	2
Phase II Trials Products	4	4	4
Phase III Trials Products	1	2	4
Pre-Clinical Phase Products	1	1
Properties	2	3	2